Qiming Venture Partners USA was launched in 2017 as the U.S. arm of a China-based venture firm, giving the biotech and healthcare companies it backs direct access to China and Asia for faster, more capital-efficient drug development, as shown with Candid Therapeutics and Umoja Biopharma. Beyond typical funding rounds, the firm also helps build companies from the ground up, backs technically ambitious projects like in vivo CAR-T with in-house manufacturing, and invests in healthcare-adjacent areas like federated AI infrastructure, all while growing to a $260 million third fund by 2022 without moving away from its healthcare focus.